SEC Form 4	
FORM	4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average but	urden							
hours per response:	0.5							

\_ . . \_ . \_ \_ \_ . . .

intended to satis defense conditio 1(c). See Instruc	ns of Rule 10b5-						
	ss of Reporting Perso DOUGLAS K	on <sup>*</sup>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>Aquestive Therapeutics</u> , Inc. [ AQST ]		ationship of Reporting Pe k all applicable) Director	erso	n(s) to Issuer 10% Owner
(Last) 201 MAIN STR	(First) EET, SUITE 2100	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 12/02/2024		Officer (give title below)		Other (specify below)
(Street) FORT WORTH	ТХ	76102	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ividual or Joint/Group Filing (Check Form filed by One Reporting Per Form filed by More than One R Person		ing Person
(City)	(State)	(Zip)					

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr.4. Securities Acquired (/ Disposed Of (D) (Instr. 3 and 5)		ed (A) or tr. 3, 4	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	12/02/2024		G		40,000	D	\$ <mark>0</mark>	199,841(1)	Ι	See Footnote <sup>(1)</sup>
Common Stock								12,585	D	
Common Stock								1,688,639	I	See Footnotes <sup>(2)(3)(4)</sup>
Common Stock								3,468,747	I	See Footnotes <sup>(2)(3)(5)</sup>
Common Stock								2,657,943	I	See Footnotes <sup>(2)(3)(6)</sup>
Common Stock								47,051	I	See Footnotes <sup>(2)(3)(7)</sup>
Common Stock								1,948,578	I	See Footnotes <sup>(2)(3)(8)</sup>
Common Stock								2,727 <sup>(9)</sup>	I	See Footnote <sup>(9)</sup>

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Dispe of (D	r osed ) r. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y	ate	Deriv	unt of rities rlying ative rity (Instr.	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

### Explanation of Responses:

1. These shares of common stock of Aquestive Therapeutics, Inc. (the "Issuer") are held by family trusts and entities controlled by Douglas K. Bratton. Such shares of common stock were acquired in previously reported in-kind pro rata distributions for no consideration without a change in pecuniary interest.

2. These shares of common stock of the Issuer are beneficially owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, Rx, Monoline Rx, Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton") is the general partner of each of the Monoline Entity". Bratton Capital Management, L.P. ("Bratton") is the general partner of Bratton and has voting and investment power over all shares held by the Monoline Entities.

3. Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares beneficially owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol (as defined below). Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein.

4. These shares of common stock of the Issuer are beneficially owned by Monoline Rx.

5. These shares of common stock of the Issuer are beneficially owned by Monoline II.

6. These shares of common stock of the Issuer are beneficially owned by Monoline III.

7. These shares of common stock of the Issuer are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. Douglas K. Bratton is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol.

8. These shares of common stock of the Issuer are beneficially owned by Monoline.

9. These shares of common stock of the Issuer are held by Douglas K. Bratton's spouse. Such shares of common stock were acquired by Douglas K. Bratton's spouse in previously reported in-kind pro rata distributions for no consideration without a change in pecuniary interest.

#### DOUGLAS K. BRATTON, 12/04/2024

Name: /s/ Douglas K. Bratton \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.